• VYD2311: A Game-Changer for COVID-19? New Antibody Boasts 139-Day Half-Life! Brought to you by Avonetics.com

  • Feb 5 2025
  • Length: 25 mins
  • Podcast

VYD2311: A Game-Changer for COVID-19? New Antibody Boasts 139-Day Half-Life! Brought to you by Avonetics.com

Listen for free

View show details

  • Summary

  • Exciting clinical trial results reveal VYD2311, a monoclonal antibody treatment for COVID-19, with a half-life exceeding 139 days! Could this be a long-lasting alternative to vaccination, especially for immunocompromised individuals? Experts weigh in on its effectiveness, cost, and how it stacks up against treatments like Paxlovid. While some raise concerns about pricing and its temporary protection, others see hope in its potential impact. Is this the future of COVID-19 defense? Join the conversation! For advertising opportunities, visit Avonetics.com.
    Show more Show less
Show more Show less

What listeners say about VYD2311: A Game-Changer for COVID-19? New Antibody Boasts 139-Day Half-Life! Brought to you by Avonetics.com

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available